Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1998-10-6
|
| pubmed:abstractText |
Obsessive-compulsive disorder (OCD) has been linked to abnormal function of brain serotonin (5-HT) pathways. Since ondansetron is a highly selective 5-HT3 receptor antagonist, the present study was undertaken to investigate 5-HT3 function in OCD. We administered m-CPP (0.08 mg/kg i.v.) and the potent 5-HT3 antagonist, ondansetron (0.15 mg/kg i.v.), to 11 OCD patients. All of the subjects received four separate challenges (m-CPP + placebo, m-CPP + ondansetron, ondansetron + placebo and placebo + placebo). In comparison to placebo, administration of m-CPP was associated with significant behavioral effects, particularly self-rated measures of anxiety, altered self-reality, functional deficit and OCD symptoms. Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms. After administration of m-CPP relative to placebo, significant increases in plasma cortisol and prolactin were found. These changes were not affected by ondansetron. In conclusion, our results do not support the hypotheses that 5-HT3 receptor-mediated mechanisms modulate m-CPP's behavioral and neuroendocrine effects in patients with OCD.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-(3-chlorophenyl)piperazine,
http://linkedlifedata.com/resource/pubmed/chemical/Ondansetron,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Receptor Agonists
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0165-1781
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
2
|
| pubmed:volume |
79
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
11-20
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:9676822-Adult,
pubmed-meshheading:9676822-Analysis of Variance,
pubmed-meshheading:9676822-Behavioral Symptoms,
pubmed-meshheading:9676822-Double-Blind Method,
pubmed-meshheading:9676822-Drug Interactions,
pubmed-meshheading:9676822-Female,
pubmed-meshheading:9676822-Humans,
pubmed-meshheading:9676822-Injections, Intravenous,
pubmed-meshheading:9676822-Intervention Studies,
pubmed-meshheading:9676822-Male,
pubmed-meshheading:9676822-Middle Aged,
pubmed-meshheading:9676822-Neurosecretory Systems,
pubmed-meshheading:9676822-Obsessive-Compulsive Disorder,
pubmed-meshheading:9676822-Ondansetron,
pubmed-meshheading:9676822-Piperazines,
pubmed-meshheading:9676822-Psychiatric Status Rating Scales,
pubmed-meshheading:9676822-Receptors, Serotonin,
pubmed-meshheading:9676822-Serotonin Antagonists,
pubmed-meshheading:9676822-Serotonin Receptor Agonists,
pubmed-meshheading:9676822-Time Factors
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
|
| pubmed:affiliation |
Section on Clinical Neuropharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|